Resources

Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C

Showing 1 to 10 of 24 resources

  • Road to Elimination: Barriers and Best Practices in Hepatitis C Management
    This report provides an overview of the status of HCV care in Europe and Australia. Through literature review and country experts’ consultation conducted between November 2016 and March 2017, the report analyses the status of 11 countries, identifying and comparing key success factors and main barriers for each step of the HCV care cascade: (1) awareness and prevention; (2) testing and diagnosis; (3) linkage to care and access to qualified health services; (4) access to medication; and (5) monitoring and evaluation.
    UK, Rest of World Reports & Research, Strategy & Planning PDF
  • Reduction in Liver Transplant Wait-Listing in the Era of Direct-Acting Antiviral Therapy
    This paper analyses trends in liver transplant wait-listing to explore the potential impact of direct acting antiviral (DAA) treatments for hepatitis C on wait-listing registration. The authors conclude that the rate of liver transplant wait-listing for hepatitis C complicated by decompensated cirrhosis has decreased by over 30% in the era of DAA therapy. Further reductions in wait-listing are anticipated with increased testing, linkage to care, and access to DAA therapy.
    Rest of World Reports & Research PDF
  • Hepatitis B and C testing activities, needs, and priorities in the EU/EEA
    Hepatitis B and C virus infections are associated with a considerable burden of disease in Europe. The European Centre for Disease Prevention and Control undertook a survey to assess needs and priorities prior to developing guidance on testing and screening for hepatitis B and C in the EU/EEA, and to update the existing evidence on the burden of HBV/HCV morbidity and mortality across EU/EEA Member States.
    Rest of World Reports & Research PDF
  • Global Hepatitis Report 2017
    This WHO Global hepatitis report describes the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.

    Rest of World Apr 2017 Reports & Research PDF
  • Guidelines on hepatitis B and C testing
    These are the first WHO guidelines on testing for chronic hepatitis B and C infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for hepatitis B and C, and are intended for use across age groups and populations.
    Rest of World Feb 2017 Other, Strategy & Planning PDF
  • The 2016 Hep-CORE Report: Monitoring the implementation of hepatitis B and C policy recommendations in Europe
    Published by the European Liver Patients Association, this report provides an overview of the progress made in tackling hepatitis B and C across different European countries, on the basis of surveys undertaken with patient organisations.
    Rest of World Jan 2017 Reports & Research PDF
  • Drug-related infectious diseases in Europe
    This report provides an update on infectious diseases related to drug use in Europe for the period up to June 2016. It covers the most recent data both on infectious diseases among people who inject drugs in Europe, collected with the European Monitoring Centre for Drugs and Drug Addiction Drug-related infectious diseases (DRID) indicator, and on the responses in the area. It includes highlights and new findings discussed during the DRID indicator’s annual expert meeting, held in Lisbon on 6–8 June 2016.
    Rest of World Reports & Research PDF
  • Global report on access to hepatitis C treatment - Focus on overcoming barriers
    This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome.

    Rest of World Oct 2016 Reports & Research PDF
  • EASL Recommendations on Treatment of Hepatitis C 2016
    These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the current optimal management of patients with acute and chronic HCV infections. These recommendations apply to therapies that have been approved by the European Medicines Agency and other national European agencies at the time of their publication.
    Rest of World Sep 2016 Other, Reports & Research PDF
  • Extrahepatic manifestations of chronic hepatitis C infection
    This research article provides an overview of the extrahepatic (i.e. non-liver) impact of hepatitis C, which include cardiovascular, renal, metabolic and central nervous system diseases.
    UK, Rest of World Aug 2016 Reports & Research PDF

Pages